Could Decreased Reporting of Suspected Adverse Reactions Generate Future Safety Concerns?

Abstract

Get full access to this article

View all access options for this article.

References

WHO. Pharmacovigilance. WHO. Last update October 2021. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en

Montastruc

J-L

Sommet

Bagheri

Lapeyre-Mestre

Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905-908.

Faillie

J-L.

Case-non case studies: principles, methods, bias and interpretation. Therapie. 2018;73:247-255.

Italian Agency of Pharmacy. Last Accessed December 2021. https://www.aifa.gov.it/rete-nazionale-di-farmacovigilanza

Muralidar

Ambi

Sekaran

Krishnan

UM.

The emergence of COVID-19 as a global pandemic: understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85-100. doi:10.1016/j.biochi.2020.09.018

Vitiello

Porta

Pianesi

Ferrara

COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci. Published online March 12, 2021. doi:10.1007/s11845-021-02584-5